Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa: results of qualitative interviews in Japan

Abstract Background Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is a rare X-linked metabolic disorder predominantly affecting males. Pabinafusp alfa, an iduronate-2-sulfatase enzyme designed to cross the blood-brain barrier, was approved in Japan in 2021 as the first enzyme replaceme...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Kimitoshi Nakamura, Norio Sakai, Mohammad Arif Hossain, Julie B Eisengart, Tatsuyoshi Yamamoto, Kazunori Tanizawa, Sairei So, Mathias Schmidt, Yuji Sato
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-03-01
סדרה:	Orphanet Journal of Rare Diseases
נושאים:	Mucopolysaccharidosis type II Hunter syndrome Caregiver-reported outcomes Pabinafusp alfa Treatment experience Quality of life
גישה מקוונת:	https://doi.org/10.1186/s13023-024-03112-1
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!